Quantcast

Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Richard Rubino, Chief Financial Officer, will present an Aerie
overview and provide a business update at two upcoming investor
conferences:

  • Raymond James Life Sciences and MedTech Conference

    • Date: Tuesday, June 18, 2019
    • Time: 9:45 a.m. ET
    • Location: New York, NY
    • Presentation Format: Corporate Presentation
  • JMP Securities Life Sciences Conference

    • Date: Wednesday, June 19, 2019
    • Time: 3:00 p.m. ET
    • Location: New York, NY
    • Presentation Format: Fireside Discussion

The presentation and fireside discussion will both be webcast live and
may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com.
A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retinal diseases and
other diseases of the eye. Aerie’s first product, Rhopressa® (netarsudil
ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S.
Food and Drug Administration (FDA) for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More information
about Rhopressa®, including the product label, is available
at www.rhopressa.com.
Aerie’s second product for the reduction of elevated IOP in patients
with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil
and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only
fixed-dose combination of Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost, has been
approved by the FDA and was launched in the United States in the second
quarter of 2019. In clinical trials of Rocklatan®, the most
common adverse reactions were conjunctival hyperemia, corneal
verticillata, instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan®, including the product label, is
available at www.rocklatan.com.
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic macular
edema. More information is available at www.aeriepharma.com.

Contacts

Media: Tad Heitmann 949-526-8747; [email protected]
Investors:
Ami Bavishi 908-947-3949; [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.